17,261 trials
Non-alcoholic Steatohepatitis
Primary: Analysis of Absolute Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) — -2.3…
Atopic Dermatitis
Primary: Percent Change of Total Eczema Area and Severity Index (EASI) Score — -51.47; -58.24 Percentage
Platysma Prominence
Primary: Percentage of Participants With at Least 1-Grade Improvement at Day 14 as Rated by Investigator Using the Clinician Allergan Platysma Prominence Scale (C-APPS) — 12.0…
Metastatic Merkel Cell Carcinoma
Primary: Objective Response Rate (ORR) — 52.3 percentage of participants
Acute Postoperative Pain · Bunionectomy
Primary: Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) of Pain Intensity Scores From Time 0 (When First Dose on Day 1 is Administered) Through 24 Hours…
Alcohol Use Disorder
Primary: Trough CBD Plasma Levels — 0; 0.7 CBD (ng/mL)
Progressive Multiple Sclerosis
Primary: Number of Participants With at Least One Treatment-related Adverse Event — 10; 7 Participants
Coronavirus Disease (COVID-19)
Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination — 6.0; 82.7; 0.0; 2.0 percentage of participants
Metastatic Cancer · Solid Tumors
Primary: Dose Limiting Toxicities (DLT) — 0; 1; 0 toxicities
Obesity
Primary: Weight Loss Kg — -0.53; -4.37 kg
Carcinoma, Non-Small-Cell Lung · Lung Cancer · Non-small Cell Lung Cancer
Primary: Dose Limiting Toxicity — 0; 0; 1; 0 Participants
Atopic Dermatitis
Primary: Change From Baseline in Eczema Area and Severity Index (EASI) Score at Day 43 — -2.64; -2.36 score on a scale — p=0.632
Clinical Stage III Cutaneous Melanoma AJCC v8 · Clinical Stage IV Cutaneous Melanoma AJCC v8 · Melanoma of Unknown Primary
Primary: Progression Free Survival — 2.7; 3.1 months — p=0.04
Breast Cancer
Primary: Collect Data to Refine and Verify the Tumor Detection Algorithm. — 11.3 Percentage
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16 — 31.8; 48.9 percentage of participants — p=0.189